172 chapter 2 Table 34. Distribution of results and availability of histopathology of Afirma® GEC in indeterminate thyroid nodules all indeterminate TN indeterminate TN with available histopathology reference ni test + test - test ? nH (% of ni with conclusive test) test + test - test ? Alexander 2012 210 123 (59%) 87 (41%) 210 (100%) 123 (100%) 87 (100%) Alexander 2014 326 139 (43%) 170 (52%) 17 (5%) 124 (40%) 113 (81%) 11 (6%)* n.s. Harrell 2014 58 36 (62%) 20 (34%) 2 (7%) 35 (63%) 30 (83%) 5 (25%) n.s. Lastra 2014 132 62 (47%) 70 (53%) 50 (38%) 48 (77%) 2 (3%) McIver 2014 72 44 (61%) 16 (22%) 12 (17%) 36 (60%) 32 (73%) 4 (25%) n.s. Sullivan 2014 14 7 (50%) 6 (43%) 1 (7%) 7 (54%) 6 (86%) 1 (17%) n.s. Brauner 2015 72 45 (63%) 26 (36%) 1 (1%) 46 (65%) 43 (96%) 3 (12%) n.s. Celik 2015 40 23 (58%) 11 (28%) 6 (15%) 20 (59%) 18 (78%) 2 (18%) n.s. Marti 2015 165 104 (63%) 61 (37%) 70 (42%) 63 (61%) 7 (11%) Noureldine 2015 222 197 (89%) 18 (8%) 7 (3%) 183 (85%) 171 (87%) 12 (67%) n.s. Witt 2016 32 15 (47%) 14 (44%) 3 (9%) 15 (52%) 15 (100%) 0 (0%) n.s. Wu 2016 214 107 (50%) 90 (42%) 17 (8%) 95 (48%) 81 (76%) 14 (16%) n.s. Yang 2016 189 94 (50%) 80 (42%) 15 (8%) 67 (39%) 62 (66%) 5 (6%) n.s. TOTAL 1,746 996 (57.0%) 669 (38.3%) 81 (4.6%) 958 (57.5%) 805 (80.8%) 153 (22.9%) *: may include ≥1 and ≤4 nodules with Bethesda V cytology, that were not clearly distinguished in the article. GEC+: suspicious GEC test result. GEC-: benign GEC test result. GEC?: nondiagnostic (n=77) or unknown (n=4) GEC test result. nH: number of indeterminate thyroid nodules with conclusive index test and available histopathology. ni: number of indeterminate thyroid nodules. n.s.: not specified.
RkJQdWJsaXNoZXIy MTk4NDMw